Glaxo hid the risks of his star drug against diabetes.
The Spanish Medication Agency has suspended the marketing of medicines containing Rosiglitazone (Avandia®, Avandamet®, Avaglim®) due to serious cardiovascular risks (myocardial infarction, heart failure and others).Marketing in 2000, about 80,000 people take it in Spain.In the world, drug sales accounted for 920 million euros last year, 2.7% of Glaxo sales.The complaints about the Rosiglitazone have been constant and there are data that allow to affirm that the laboratory was aware of the importance of its adverse effects.
No signature configured, update it from user's profile.
In my opinion Glaxo hid unfavorable studies, it's true, but prospects are quite clear ... Do not take Avandia * If it is allergic (hypersensitive) to Rosiglitazona or any of the other Avandia components (collected in section 6) * If you have suffered a severe heart attack or angina, which has been treated in the hospital * If you suffer from heart failure, or have suffered heart failure in the past * If you suffer from a liver disease * If you suffer from diabetic ketoacidosis (a complication of diabetes with symptoms of rapid weight loss, nausea or vomiting, which can trigger diabetic pre-chart)
Consult your doctor if you suffer from any of these symptoms.Do not take Avandia.
Have special care with Avandia
The entire prospect:
To those who have to ask for responsibilities is the European and American agencies that authorized their commercialization without having irrefutable evidence that the medication was safe. The same ones who authorized and swallowed Glaxo's alleged deception continue in his position and continue to evaluate other medications.
